CDMO Recro expands manufacturing capabilities at former Alkermes site

By Melissa Fassbender

- Last updated on GMT

Recro Gainesville is an FDA- and DEA-approved solid oral dose manufacturing services provider. (Image: iStock/dolgachov)
Recro Gainesville is an FDA- and DEA-approved solid oral dose manufacturing services provider. (Image: iStock/dolgachov)

Related tags Pharmacology

Recro has added a new tablet manufacturing suite that enables it to compress single- and bi-layer tablets at commercial speeds.

Recro Gainesville LLC is a wholly-owned subsidiary of Recro Pharma Inc. and provides solid oral dose manufacturing services with a specialization in extended release and controlled substances.

The company's Gainesville, Georgia-based site was acquired​ from the pharmaceutical company Alkermes in 2015.

As Outsourcing-Pharma.com previously reported​, Recro also gained worldwide rights to Alkermes' Phase III long acting pain drug IV/IM meloxicam in return for potential milestone payments as part of the $50m facility divestiture deal.

The company’s new suite now includes the Fette FE 55 tablet press and a new film coater, the Bohle BTC-100, both of which the company said will enable it to compress single- and bi-layer tablets at commercial speeds.

The contract manufacturing and development organization (CDMO) has also added nearly a dozen scientist to its team.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars